Citigroup Inc Homology Medicines, Inc. Transaction History

Citigroup Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 09, 2023	SELL	$1.09 - $2.04 $28,904 - $54,096	-26,518 Reduced 29.95%	62,015 $78,000
Q3 2022 Nov 10, 2022	SELL	$1.55 - $3.01 $204,014 - $396,182	-131,622 Reduced 59.79%	88,533 $143,000
Q2 2022 Aug 10, 2022	BUY	$1.39 - $3.12 $300,142 - $673,701	215,930 Added 5110.77%	220,155 $434,000
Q1 2022 May 12, 2022	SELL	$2.6 - $4.17 $23,036 - $36,946	-8,860 Reduced 67.71%	4,225 $13,000
Q4 2021 Feb 10, 2022	BUY	$3.64 - $7.78 $17,191 - $36,744	4,723 Added 56.48%	13,085 $48,000
Q3 2021 Nov 10, 2021	BUY	$6.01 - $8.71 $50,255 - $72,833	8,362 New	8,362 $66,000

66.2K

Ticker FIXX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 57,402,000
Description
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nucleas...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.